CLUSTER filed Sep 2, 2026 at 16:01 ET
Five senior executives at Ocular Therapeutix, including the Chief Scientific Officer, Chief Operating Officer, and Chief Development Officer, sold a total of ~$333K in shares over a one-week period. While the dollar amount is modest relative to the $2.4B market cap (0.01%), the cluster involves multiple C-suite insiders selling on the same day, which warrants attention despite the academic literature showing cluster sales are less informative than buys. The sales follow a strong recent stock performance and occur ahead of potential pipeline catalysts for the company's lead drug candidate.